Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd

₹ 1,559 0.77%
03 Dec - close price
About

Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.[1]

Key Points

Leadership[1]

<h1>14th largest and fastest growing in the Indian market</h1> <h1>15th largest generic company by prescriptions filled in the USA</h1> <h1>5th largest Indian generic co. in Europe.</h1>
  • Market Cap 43,935 Cr.
  • Current Price 1,559
  • High / Low 1,831 / 767
  • Stock P/E
  • Book Value 299
  • Dividend Yield 0.16 %
  • ROCE 12.3 %
  • ROE -50.9 %
  • Face Value 1.00

Pros

  • Company has reduced debt.
  • Debtor days have improved from 88.3 to 57.4 days.
  • Company's working capital requirements have reduced from 96.9 days to 31.8 days

Cons

  • Stock is trading at 5.21 times its book value
  • The company has delivered a poor sales growth of 3.67% over past five years.
  • Company has a low return on equity of -10.6% over last 3 years.
  • Company's cost of borrowing seems high

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
3,147 3,173 3,019 2,777 3,018 3,100 3,001 3,036 3,207 2,507 3,063 3,244 3,434
2,557 2,480 2,556 2,346 2,539 2,626 2,603 2,599 2,745 2,715 2,559 2,656 2,832
Operating Profit 590 693 463 432 479 474 398 437 462 -209 504 588 602
OPM % 19% 22% 15% 16% 16% 15% 13% 14% 14% -8% 16% 18% 18%
-13 -164 25 183 86 209 -696 -32 -205 87 351 31 39
Interest 69 67 87 60 83 97 109 112 121 134 149 40 48
Depreciation 123 119 132 147 146 152 135 142 141 147 151 118 120
Profit before tax 385 343 270 408 337 435 -542 151 -6 -403 555 462 473
Tax % 29% 30% 36% 48% 17% 33% -26% -14% 997% -18% 319% 26% 25%
275 240 173 211 279 291 -403 173 -62 -331 -1,214 340 354
EPS in Rs 9.13 7.86 5.51 6.82 9.23 9.66 -15.18 5.31 -2.90 -12.45 -43.17 12.06 12.55
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
5,012 6,005 6,563 7,562 9,079 9,074 9,865 10,641 10,944 12,305 11,583 11,813 12,248
3,997 4,914 5,348 6,125 7,043 7,457 8,280 8,942 8,860 9,978 9,948 10,618 10,762
Operating Profit 1,015 1,091 1,214 1,437 2,037 1,617 1,586 1,699 2,084 2,327 1,635 1,195 1,486
OPM % 20% 18% 18% 19% 22% 18% 16% 16% 19% 19% 14% 10% 12%
11 11 -180 20 -44 89 375 191 95 -101 -10 336 509
Interest 160 189 190 179 237 286 335 377 353 298 349 516 371
Depreciation 127 217 300 234 264 302 326 417 444 487 569 582 536
Profit before tax 739 697 544 1,044 1,491 1,119 1,301 1,096 1,382 1,441 707 434 1,087
Tax % 15% 22% 61% 29% 26% 28% 29% 29% 30% 31% 47% 430%
628 546 209 743 1,109 804 925 776 970 994 377 -1,434 -850
EPS in Rs 22.89 19.99 7.72 26.33 39.29 28.49 32.78 27.50 34.38 33.37 10.53 -53.22 -31.01
Dividend Payout % 0% 0% 26% 8% 5% 7% 6% 9% 7% 7% 24% -5%
Compounded Sales Growth
10 Years: 7%
5 Years: 4%
3 Years: 3%
TTM: -1%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -454%
Stock Price CAGR
10 Years: 7%
5 Years: 37%
3 Years: 46%
1 Year: 101%
Return on Equity
10 Years: 5%
5 Years: -3%
3 Years: -11%
Last Year: -51%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 27 27 27 28 28 28 28 28 28 28 28 28 28
Reserves 2,736 2,956 1,756 3,601 4,464 5,135 5,577 6,042 7,036 9,058 9,446 7,820 8,417
2,765 3,267 3,800 3,988 4,724 4,639 4,449 4,869 4,986 3,962 4,608 1,231 1,711
1,466 2,176 2,726 2,575 2,548 2,793 3,235 3,729 3,524 4,003 5,289 5,279 5,009
Total Liabilities 6,994 8,427 8,309 10,193 11,764 12,595 13,289 14,668 15,575 17,052 19,371 14,358 15,165
2,822 3,091 2,015 2,594 2,755 3,030 3,670 5,029 5,129 5,887 5,422 4,210 4,507
CWIP 6 5 477 543 708 1,122 1,399 1,222 1,382 1,010 1,190 662 395
Investments 0 0 17 17 16 15 30 25 25 50 45 790 45
4,166 5,331 5,799 7,039 8,285 8,429 8,190 8,393 9,040 10,105 12,715 8,697 10,219
Total Assets 6,994 8,427 8,309 10,193 11,764 12,595 13,289 14,668 15,575 17,052 19,371 14,358 15,165

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
648 854 482 345 657 1,648 1,324 1,392 1,131 1,109 625 -265
-558 -566 -712 -950 -1,001 -1,003 -883 -774 -662 -316 -515 4,387
195 -98 199 699 543 -468 -739 -445 -442 -520 -77 -3,906
Net Cash Flow 285 190 -31 93 199 177 -297 174 28 272 32 215

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 119 131 140 120 97 94 81 83 86 92 115 57
Inventory Days 194 191 247 249 299 244 244 211 230 208 203 208
Days Payable 239 279 379 308 243 225 241 210 226 190 172 210
Cash Conversion Cycle 75 43 8 61 152 113 85 84 90 110 147 56
Working Capital Days 94 83 66 89 133 111 76 69 96 100 159 32
ROCE % 18% 15% 16% 19% 21% 15% 15% 14% 15% 16% 10% 12%

Shareholding Pattern

Numbers in percentages

Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65%
24.18% 24.12% 24.23% 23.14% 23.19% 22.47% 25.51% 24.79% 23.71% 21.38% 20.98% 23.05%
10.86% 10.96% 10.50% 10.90% 10.69% 10.40% 9.10% 10.31% 10.92% 13.36% 13.93% 13.21%
0.00% 0.00% 0.00% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04%
18.31% 18.27% 18.63% 19.27% 19.45% 20.46% 18.70% 18.21% 18.70% 18.58% 18.42% 17.06%
No. of Shareholders 3,17,3833,10,5163,12,4733,13,5403,00,1062,85,4612,36,9082,32,6852,09,9311,99,4511,92,6301,93,949

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls